04 — Bioanalysis: Non-Clinical Stage
Overview
Non-clinical bioanalysis of ADCs supports pharmacokinetic (PK) studies in animals, safety/toxicology programs, and go/no-go decisions before first-in-human (FIH) dosing. Regulatory expectation: data generated under GLP or pre-GLP (fit-for-purpose) standards, with methods qualified or validated per FDA/ICH guidance.
1. Analyte Hierarchy
ADC bioanalysis is uniquely complex because one molecule generates multiple distinct analytes that coexist in circulation. Each analyte answers a different biological question.
Intact ADC (DAR 2, 4, 6, 8)
│
├── Total Antibody (TAb) ← all antibody forms, regardless of conjugation status
├── Conjugated Antibody (cAb) ← antibody with ≥1 payload attached
├── Total ADC ← sometimes used as synonym for cAb; context-dependent
├── Conjugated Payload ← payload still attached to antibody (measured by hybrid LBA-MS)
└── Free Payload ← unconjugated cytotoxic drug circulating in plasma
| Analyte | What it Measures | Biological Meaning | Primary Assay |
|---|---|---|---|
| Total Antibody (TAb) | All antibody (conjugated + deconjugated) | Antibody PK, FcRn-mediated half-life | LBA (sandwich ELISA; anti-Fc capture, anti-Fab detect) |
| Conjugated Ab (cAb) | Antibody retaining ≥1 payload | Effective ADC exposure; deconjugation rate | LBA (drug-binding or drug-linker reagent in detection) |
| Free Payload | Unconjugated cytotoxic drug | Off-target toxicity driver; linker stability readout | LC-MS/MS (protein precipitation + extraction) |
| Conjugated Payload | Total payload still on antibody | DAR-weighted ADC exposure | Hybrid LBA-LC/MS/MS |
| Catabolites | Intracellular or systemic degradation products | Defines active metabolites contributing to PD | LC-MS/MS or LC-HRMS |
2. Assay Platforms
2a. Ligand-Binding Assays (LBA/ELISA)
Total Antibody (TAb) ELISA:
- Capture: Anti-Fc antibody (binds Fc region regardless of payload status)
- Detection: Anti-idiotype antibody (unique to the therapeutic mAb, binds Fab) OR anti-target antigen
- Standard: Naked antibody (unconjugated parent mAb) — same epitope regardless of DAR
- Limitation: Cannot distinguish DAR0 (naked Ab) from DAR8; measures all species equally
Conjugated Antibody (cAb) ELISA:
- Capture: Anti-Fc antibody
- Detection: Anti-drug (anti-payload) antibody OR anti-linker-payload reagent
- Key design consideration: Detection reagent must bind the drug/linker moiety — requires either an anti-drug antibody or a proprietary anti-linker reagent
- Limitation: Signal intensity varies with DAR (DAR4 gives ~2× signal vs. DAR2 vs. same molar concentration); calibrator must be characterized for average DAR
Alternative cAb formats:
- Capture on antigen (target protein-coated plate) + anti-drug detection: very selective, less prone to matrix interference
- Affinity capture + LC-MS/MS (hybrid): see section 2c
2b. LC-MS/MS for Free Payload
Free payload quantification is critical because:
- It reflects linker instability in circulation (premature payload release)
- Free payload drives off-target toxicity (myelosuppression, neurotoxicity, etc.)
- PK profile of free payload is distinct from ADC (smaller MW, different distribution)
Typical method workflow:
- Protein precipitation (ACN or MeOH, 3:1 v/v) or supported liquid extraction (SLE) or mixed-mode SPE
- Centrifugation; supernatant evaporation
- Reconstitution in aqueous/organic mobile phase
- Reverse-phase LC (C18, 2.1 × 50 mm, 1.7 µm) with gradient elution
- ESI-positive mode, MRM transition (parent → product ion)
LLOQ targets: Typically 0.1–1 ng/mL (species-dependent; must cover expected free payload from ADC dose)
Payload-specific considerations:
| Payload | Key Analytical Challenge |
|---|---|
| MMAE | Non-specific binding to plasticware; use protein lo-bind tubes; monitor for carryover |
| DM1/DM4 | Multiple catabolite forms (Lys-SMCC-DM1 vs. free DM1); define which catabolite to measure |
| DXd | Lactone/carboxylate equilibrium; stabilize with formic acid; measure total DXd (lactone + carboxylate) |
| SN-38 | Lactone ring opens at pH > 6; acidify immediately; measure total vs. lactone forms |
| Calicheamicin | Extremely potent, ultra-low concentrations; needs HRMS or ultra-sensitive MRM |
2c. Hybrid LBA-LC/MS/MS (Conjugated Payload Measurement)
The hybrid assay bridges the selectivity of an LBA capture step with the specificity of MS quantitation.
Workflow:
- Affinity capture: Incubate plasma with biotinylated antigen or anti-Fc antibody on streptavidin beads → captures all Ab-containing species (TAb)
- On-bead digestion or chemical release: Release payload from captured antibody using DTT/reduction (disulfide linkers) or enzymatic digest (protease)
- LC-MS/MS quantitation: Measure released payload by MRM
Advantages over direct ELISA:
- Directly quantifies payload molecules per antibody (enables average DAR calculation from PK data)
- Not dependent on anti-drug antibody reagents (which may be difficult to develop for small payloads)
- Species-independent — no need for species-specific detection reagents
Regulatory acceptance: Increasingly accepted by FDA/EMA for cAb measurement; recommended in emerging ADC bioanalysis white papers (AAPS ADC working group).
3. PK Parameters — Non-Clinical ADC Studies
Typical analytes and their PK parameters tracked in animal (rat, monkey) PK studies:
| Parameter | Typical ADC (cAb) | Free Payload |
|---|---|---|
| Cmax | µg/mL range | ng/mL range |
| T½ | 3–7 days (rodent); 7–14 days (monkey) | Hours to 1–2 days |
| AUC₀–∞ | Large, dose-proportional (often) | Small; driver of tox |
| Vd | ~50–100 mL/kg (IgG-like) | Larger (distributed to tissues) |
| Clearance | 3–10 mL/day/kg | Faster, hepatic/renal |
Species differences relevant to ADC non-clinical PK:
- Cathepsin B activity: Generally conserved across species; Val-Cit cleavage rates comparable between mouse, rat, monkey, and human
- FcRn binding: Human IgG1 has species-specific FcRn binding kinetics — monkey (cynomolgus, rhesus) best predicts human Ab half-life; rodent FcRn binds human IgG with lower affinity → shorter half-life in mice
- Plasma esterase: Rat plasma has higher esterase activity than human — can affect ester-containing linkers (e.g., carbamate esters in some linkers); use Na-fluoride tubes + sodium azide for rat plasma if needed
- Target expression: Inter-species antigen cross-reactivity drives tissue distribution and receptor-mediated clearance
4. Sample Collection and Handling
This is a non-trivial pre-analytical factor for ADCs:
| Issue | Recommendation |
|---|---|
| Blood collection tubes | K₂EDTA preferred; avoid serum (clotting activates proteases) |
| Temperature | Process on wet ice; centrifuge at 4°C; store at –70°C to –80°C |
| Free payload stabilization | Add esterase inhibitor (NaF) or acid if payload is ester/lactone-containing; pre-cool tubes |
| Avoid freeze-thaw cycles | ADC stability must be confirmed (typically ≤3 cycles acceptable) |
| Matrix choice | Plasma preferred over serum; specify species (rat, monkey, human) and anticoagulant |
| Hemolysis | Document and exclude severely hemolyzed samples (hemoglobin releases GSH → can cleave disulfide linkers) |
5. Regulatory Framework (Non-Clinical)
| Guideline | Application |
|---|---|
| FDA Guidance on Bioanalytical Method Validation (2018) | Overarching BMV requirements; applies to non-clinical if used to support safety |
| ICH M10 (2022) | Harmonized BMV; references LBA and chromatographic methods |
| FDA Guidance for Industry: Immunogenicity Assessment (2019) | ADA in non-clinical (monkeys) if needed for repeat-dose toxicity |
| ICH S9 | Non-clinical safety studies for oncology ADCs — supports abbreviated tox package |
| AAPS white papers (2014, 2020) | ADC-specific bioanalysis recommendations (not regulatory guidance but industry consensus) |
Fit-for-purpose (FFP) methods: For early-stage discovery/lead optimization, FFP qualification is acceptable. Full GLP validation is required for pivotal toxicology studies (used in IND).
Key Papers & Resources
- Kaur et al. (2013) AAPS J — recommended analytes for ADC PK studies (AAPS ADC working group)
- Gorovits et al. (2013) Bioanalysis — hybrid LBA-LC/MS/MS for conjugated payload
- Xu et al. (2011) Drug Metab Dispos — T-DM1 non-clinical PK and catabolite profiling
- FDA BioA Guidance (2018)
- ICH M10 Bioanalytical Method Validation (2022)